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Kratom (Mitragyna speciosa) is a tree native to Southeast Asia with long history of 
traditional medicinal use. The aim of this study was to investigate the nature of self-
reported exported experiences as shared on YouTube™ videos. A total of 500 videos 
with 19,478,180 views and 134, 863 comments emerged from the data scrape 
extracted via the YouTube Data Tool. 12 out of the 16 most viewed videos emerged 
from our searches were manually processed and selected for inductive thematic 
analysis. Kratom use for the self-medication of a number of health conditions was 
described in the videos, including for opioid dependence/addiction (83.4%), pain 
(75%), anxiety (67%) and depression (42%), substance use problems (42%) as well as 
for energy boosting (50%), mood elevation (25%) and nootropic effects (25%). 
Although most of the described experiences were positive (58%), side-effects such as 
dependence and withdrawal (50%), nausea (42%), loss of appetite (25%), sedation 
(25%), loss of motivation (16.7%), headache (16.7%), drowsiness (16.7%), dry mouth 
and frequent urination (16.7%) were also reported and associated in 25% of the cases 
to chronic ingestions. Overall, our findings would show that Kratom is used more 
frequently for self-medication, than as a recreational drug. It also supports the need for 
more controlled clinical studies to better assess the safety and the efficacy of its use in 
a therapeutic context. 
 
Keywords: Kratom; Novel Psychoactive Substances (NPS); opioid withdrawal; 
addiction; pain 
  




Mitragyna speciosa, most commonly known as Kratom, but also Biak or Ketum, Kakuam, 
Ithang or Thom, grows native in Southeast Asia, particularly Malaysia, Thailand and Indonesia. 
With a long history of traditional medicinal use (Eastlack et al., 2020; Kruegel and Grundmann, 
2018; Singh et al., 2016; Singh et al., 2020), the leaves of this evergreen tree are consumed in local 
context for its dose-dependent stimulant and ‗opioid-like‘ effects for intensifying work efficiency, 
as a pain reliever, and to substitute opioids (Prozialeck et al., 2012; Vicknasingam et al., 2010). 
Kratom contains more than 40 different alkaloids (Shellard, 1974; Takayama, 2004), though 
the majority of its pharmacological properties are related to its two active psychoactive compounds: 
mitragynine and its metabolite 7-hydroxymitragynine (Eastlack et al., 2020; Hassan et al., 2013; 
Kruegel et al., 2019). Mitragynine displays a complex action on the Central Nervous System (CNS) 
as a full agonist of the μ-opioid receptors and as a partial agonist of δ-, and antagonist of κ-opioid 
receptors (Carpenter et al., 2016; Kruegel et al., 2016). It also acts on neuronal Ca2+ channels and 
descending noradrenergic/serotonergic system (Matsumoto et al., 1996, 2006). Furthermore, 
mitragynine is found to produce an effect on other receptors such as the serotonin (5-HT) 2A, 5-
HT2C and 5-HT7, adenosine-2a, dopamine-2, and postsynaptic alpha-2 adrenergic receptor (Boyer 
et al., 2008; Kruegel and Grundmann, 2018; Matsumoto et al., 1997). This broad pharmacological 
profile largely explains its wide, and sometimes contradictory behavioural actions at different 
titrations, some of which have been observed in animal models including anxiolytic-like (Hazim et 
al., 2014), antidepressant (Idayu et al., 2011), and antipsychotic effects (Vijeepallam et al., 2016). 
The pharmacodynamics, metabolization (Kamble et al., 2019), and the pharmacokinetic properties 
of Kratom have been mainly studied in preclinical models (Ya et al., 2019). In addition, it has been 
shown that in humans doses up 76.3–114.8 mg of mitragynine taken on a daily basis did not appear 
to cause any major health problems (Singh et al., 2018). Over the last decade, a wide range of 
Kratom products, though a substantial number was found to be adulterated, are now made available 
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widely in Western countries as well as in Japan (Maruyama et al., 2009), where they are sold on the 
internet and in smart (head) shops as a plant-based Novel Psychoactive Substance (NPS; Corazza 
and Roman-Urrestarazu, 2018). These include raw leaves, capsules, tablets, powders, and 
concentrated extracts, with little standardization of contents or potency.  
Evidence suggests that Kratom products are also recreationally used in combination with 
other substances, such as anti-depressant or anti-psychotic agents and/or opiates/opioids, 
benzodiazepines, alcohol and some NPS (e.g., designer opioids and synthetic cathinones) (Corkery 
et al., 2019). This has led to previously unreported adverse effects and fatalities, mainly in North-
Western Europe and the United States, which have not been reported in native countries (Alsarraf et 
al., 2019; Corkery et al., 2019; Singh et al., 2017). Although in 2016 the Drug Enforcement 
Administration (DEA) proposed placing Kratom into Schedule I of the Controlled Substances Act 
(CSA) because of its opioid-like abuse potential and poorly defined safety risk, the attempt was 
later halted by the outcome of a public outcry, which supported the continued legal access to 
Kratom because of its purported therapeutic benefits (Griffin and Webb, 2018; Henningfield et al., 
2018). Consequently, Kratom currently remains legal and available in the United States, where 
individuals use Kratom to self-manage various health conditions such as pain, also in Covid-19 
disease (Metastasio et al., 2020), mental health problems (e.g. ADHD, mood and anxiety disorders), 
and opioid/alcohol addiction and/or withdrawal (Bath et al., 2020; Garcia-Romeu et al., 2020; 
Swogger and Walsh, 2018). 
Despite the widespread use, the scientific evidence underlying such medical applications is 
still lacking. Most of the currently available information on the benefits of Kratom to mitigate such 
conditions are often anecdotal and shared by users on social media and internet discussion fora, 
which, in absence of clinical trials, became of paramount importance for a better understanding of 
the plant and its proprieties. For example, a previous study performed by Swogger et al. (2015) 
provided a qualitative analysis on Kratom users‘ experiences as published on Erowid, a well-known 
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website used for sharing information on psychoactive substances. Similar investigations on social 
media platforms have been carried out to study psychedelic microdosing (Hupli et al., 2019; 
Andersson and Kjellgren, 2019; Johnstad et al., 2018), Salvia divinorum use (Casselman and 
Heinrich, 2011) and use of NPS (Corazza et al., 2013; Soussan et al., 2018) as well as to contribute 
to drug education and prevention activities (Chiauzzi et al., 2013; Soussan and Kjellgren, 2014; 
Andreotta et al., 2019; Manning, 2013). 
Among social media, the YouTube™ platform has shown in previous studies to provide a 
valuable aid in the field of qualitative drug and health care research (Andersson and Kjellgren, 
2019; Casselman and Heinrich, 2011; Hasamnis and Patil, 2019; Hupli et al., 2019; Kataja et al., 
2019; Lange et al., 2010; Madathil et al., 2015). In recent years, video hosting services quickly 
became the Internet's primary hub for expression of opinions on various matters. The mere quantity 
of videos makes this medium very rich in content, and as the slogan of YouTube™ states 
―Broadcast Yourself‖, a large amount of the content is user-generated which comprise the ecology 
of YouTube alongside with traditional media sources (e.g. Burgess and Green 2009). Ethnographic 
research on YouTube™ is still rare (Wesch 2009; Burgess and Green 2009), especially around drug 
use, but as Murthy (2008: 849) has stated the "combination of participant observation with digital 
research methods [...] may provide a fuller, more comprehensive account." 
This study aims to better understand the use of Kratom and its underlying motivations, 
perceptions and potential side-effects as shared on YouTube™ platform.  
 
2. Materials and methods 
The YouTube Data Tool (YDTS 2018; Digital Methods Initiative 2018; Hupli et al., 2019; 
The Politics of Systems 2018) was used to extract data via the YouTube API (Application 
Programming Interface). The ―video list module‖ was selected to create a selection of videos 
according to a specific search query. The search word ―Kratom‖ was entered in the search query to 
extract the maximum number of iterations available (max 10 and 1 iteration gives 50 items). An 
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initial data extraction was done in July 2019, followed by a subsequent search in February 2020. 
Cut-off for inclusion in the analysis was 250,000 views. Automated English transcripts of the most 
viewed videos were created by YouTube´s machine learning algorithms, and imported as .doc files, 
including words, spaces, and correspondent times, for the subsequent qualitative analysis (see Table 
1). The latter was carried out in the form of inductive thematic content analysis, following the 
method of collaborative online interpretation (―Crowded Theory‖, see Bröer et al., 2016; Andersson 
and Kjellgren, 2019). Entries were manually revised in conjunction with a screening of the videos 
as the quality of the automated transcripts can vary and classified according to (a) the motivations 
of use/therapeutic benefits and/or other applications and (b) the reported side effects and other 
safety issues. No initial hypothesis was used, and video comments were not taken into account. The 




500 YouTube™ videos emerged from the original data scrape in July 2019, with a total of 
18,700,721 views and 135,982 comments. The number of videos was confirmed by a second data 
scrape six months after (February, 2020), where the view count increased to 19,478,180, though 
there was a decrease in the number of comments (134, 863), probably due to the dynamic nature of 
online information (Burgess and Green, 2009). Twelve (12) out of the sixteen (16) most viewed 
videos at the time of the first data extraction were selected for further thematic analysis. Four videos 
were excluded from our study (one was in German, two were no longer viewable at the time of the 
second scrape and the transcript for one of them was not generated by the program). Included 
videos had a total length of 2 h 23m 11s (average 25 min 21sec), 7,928,274 views, 111,321 likes, 
13,284 dislikes and 42,584 comments. As shown in Table 1, selected YouTube™ videos reported 
data derived from the experiences/comments of 23 individuals articulated in the form of self-
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reported experiences, sometimes discussed during an interview (9) as well as a talk show involving 
non-using experts, where different opinions were expressed about Kratom (1), a report by a science 
communicator (2), a documentary about Kratom (3). [Table 1 near here] 
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year Addiction | 
World of Hurt 
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1 User M, BT, S P 
i. n.: Identification number; m: minutes; s: seconds; M: motivations; BT: benefits and therapeutic applications; S: side effects; P: positive; N: negative; U: undetermined. 
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3.1. Motivation of use  
Kratom was described across all the analysed videos as ―a safe natural substance‖, that 
―did not seem to be a drug, but an herbal medicine‖. Claims such as ―it has been used for 
hundreds of years as a natural traditional medicine‖, with users attesting ―its powerful 
therapeutic benefits‖ were very common. In 75% of the videos (n. 1, 2, 3, 4, 7, 8, 9, 10 and 
11) both the physical and psychological benefits of Kratom consumption were described. 
These included references to an energy boost (in 50% of twelve videos) ―similar to a caffeine 
boost‖, which helped users to increase their productivity at work, combat fatigue and ―feel 
revitalized or energized‖. Nootropic effects (25%), such as an increased ―ability to 
concentrate‖ and ―to focus‖, since Kratom was described as a ―fantastic boost for 
…creativity‖ and recommended as potential ―replacement for Adderall in people who are 
currently using it to focus‖; mood elevation and euphoria (25%) (―dose of 4 to 5 grams puts 
me in a much more euphoric‖, ―…it improves your mood and makes you euphoric‖, ―two to 
three grams is enough to boost mood and put into a productive state‖); anxiolysis and 
relaxation (67%) (―it can be quite sedating‖, ―I think it's much more healthy and safe than 
Benzodiazepine‖, ―it can make someone feel very relaxed and chill‖) were also commonly 
described. Kratom was also used to complement social interactions in ―religious ceremonies‖ 
(8.4%) and its entactogenic effects were also reported (33.3%). These included ―feeling of 
empathy‖, with some users recommending ―Kratom as an alternative to drinking‖ as 
―socialization becomes more unsuppressed and effortless‖.  
Therapeutic applications were found in all videos, described as Kratom benefits in the 
67% of them (n. 1, 2, 3, 4, 5, 10, 11 and 12) by seven users and talk show participants. They 
were referred to cases of acute/chronic and ―extreme pain‖ management (75% of twelve 
videos) (―people use it really to fight pain‖, ―Kratom is a powerful analgesic‖ and ―a 
painkiller‖ better than ―every single form of opiate‖). As highlighted in Table 2, Kratom was 
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also used for ―improving health and well-being‖, detoxifying from substances of abuse (42%) 
(e.g. amphetamine), as well as for managing ―addiction‖ and ―marijuana and alcohol 
withdrawals‖. In 83.4% of the videos, some users claimed that ―Kratom reduces the intake of 
more addictive and dangerous opioids‖, ―it is the only substance that managed to get them off 
heroin‖, and ―helps people to overcome opiate/opioid addiction‖, and found to be useful in 
treating a variety of other conditions, such as ―diarrhoea‖ (8.4%), sexual desire (8.4%) 
(―Kratom may act as an aphrodisiac in women... and decrease erection problems in men‖), 
psychological disorders (42%, ―depression‖, ―PTSD and anxiety‖) and sleep problems (8.4%) 
(―I slept well…feel pretty good‖ and ―rested‖).  
[Table 2 near here] 
Table 2. Motivations of use and other applications as described by Kratom users 









―It is a less addictive treatment for pain‖ 
―It's pain cover‖ 





―All I'm hearing is it helps people with heroin addiction‖ 
―We're talking about replacing opium, heroin‖ 
―Kratom could be the very first cure for the opioid 
epidemic‖ 
―People have been using it to keep off with their 
addiction‖ 
―People were using it as an alternative to heroin and 
opiates‖ 
―Kratom is not addictive alternative to methadone or 
buprenorphine‖ 




―I would take Kratom for prescribed amphetamines‖ 
―It can help with marijuana…alcohol withdrawals‖ 
―Kratom helps people with methamphetamine problem‖ 




―If it's not for Kratom he suffers such bad depression‖ 




―It was found to have an acute ability to reduce anxiety‖ 
―People used it as alternative to anti-anxiety medication‖ 
―It also has kind of benefit as Anxiolytic‖ 







―I … recommend Kratom to anyone who needs a boost 
in focus‖ 
3 
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BENEFITS ―I'm suggesting try Kratom to those who are using … 
Adderall to focus‖ 
Energy Boost 
―It is a stimulant‖ 
―I'm feeling the energy from the Sun … my thoughts 
(are) pretty clear‖ 
―It makes you energetic and euphoric‖  
―You're very restless‖ 
6 
Mood elevation 
―Euphoric enough that you feel like going out and doing 
things‖ 
―I feel very content, like I'm covered with a warm 
blanket‖ 






―I also feel a lot more friendly‖ 
―I could just walk up to people and start a conversation‖ 
4 
 
3.2. Side effects 
We also documented the side-effects of Kratom use. Eighty-three percent of the 
videos (n. 1, 2, 3, 6, 7, 8, 9, 10, 11 and 12) showed that Kratom can cause adverse effects. 
Some (42%) claimed that users ―can become nauseous to the point where they vomit 
sometimes for hours‖, and experience headache (16.7%) (―I do not feel so good as I 
experienced long-lasting episodes of headache throughout the day‖). In addition, some of the 
commonly reported side-effects associated with Kratom use include sedation (25%), loss of 
appetite (25%), loss of motivation (they felt ―very unmotivated‖ and ―apathetic‖) (16.7%), 
drowsiness and decrease in attention (16.7%), dry mouth and frequent urination (16.7%), 
anger (16.7%), weakness and sweating (8.4%), decrease in sexual desire (8.4%), and 
dizziness (8.4%). However, from the discussions that emerged from the videos, all these 
negative effects usually occurred when someone consumes Kratom multiple times a day, and 
―there are not many choices of drugs to be safely used every day‖. ―Kratom affects your 
muscles, and eye muscles‖ and ―some users can begin to feel sedation from as little as three 
grams‖, and at 4 grams the sedating effects becomes more intense. Moreover, the other 
profound side-effects linked to the chronic use of Kratom (25%) were weight loss, insomnia, 
dark skin, constipation, dysphoria, and mild depression. Half (50%) reported that Kratom can 
cause addiction (especially for ―addictive personality‖, ―I find it can be very easy to get 
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addicted‖), dependence with tolerance (―frequent use will give you a tolerance‖), and opiate-
like withdrawal syndrome (―unfortunately for some, Kratom is also habit forming; with 
withdrawal manifesting both physically and mentally‖, ―the withdrawal…causes tremors, 
anxiety, joint and muscle, aches and limb jerks, mood swings, hostility, aggression, 
depression, insomnia, sweating, nausea, and headaches‖), and fatalities (33.3%) (―in the 
United States a total of 36 people have died from overdosing‖, related mostly to combination 
with other substances, ―14 related overdoses, none… Kratom was not alone‖, ―9 deaths were 
in Sweden and Kratom was laced with fentanyl‖). Except for severe toxicities caused by 
extreme cases of addiction (with ―jaundice and some liver toxicity‖, ―runny nose, irritability‖) 
or very high intake of Kratom use (―from 12 to 15 grams of Kratom per day‖), in normal 
doses the substance was mainly reported to be a safe drug. Supplementary information can be 
found in Table 3. 
[Table 3 near here] 
Table 3. Side effects reported by users 





―I may initially get nauseous‖ 
―I was really nauseous‖ 
5 
Loss of motivation ―I just felt really no urge to exercise anymore‖ 2 
Anger ―It always made me feel angrier…to lose my temper‖ 2 
Decrease of sexual desire ―It actually decreases the amount of testosterone‖ 1 
Weakness, Sweating 
―Feel weaker‖ 
―I'm sweating all mornings‖ 
1 
Headache 
―My head is like throbbing‖ 
―By day three and four headaches‖ 
2 
Loss of appetite 
―Kratom dehydrates you and it takes away your 
appetite‖ 
―Kratom suppresses the appetite, …you're less hungry‖ 
3 
Dry mouth and frequent urination 
―I do have a very dry mouth‖ 
―And a more frequent urge to pee‖ 
2 
Alteration in breath and blood pressure 




―Can make you extremely tired safety-wise‖ 
―I feel very tired suddenly, very listless‖ 
3 
Dizziness and decrease of attention 
―I'm about to faint‖  
―That may cause your sight to become fuzzy and 
unfocused‖  
1 
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―You can't focus anymore‖ 
Drowsy and sluggish state 
―When you take more Kratom, you may get drowsy and 
sluggish‖ 
―I just feel very tired and sluggish‖ 
2 
Effects at high doses 
―I had the runny nose‖ 
―Dizziness, especially in high doses constipation‖ 
―In high doses you run the risk of dysphoria, intense 
nausea‖ ―Dangerous and even deadly‖ 
3 
Addiction, dependence, and withdrawal 
syndrome 
―Addiction with the potential for withdrawal‖ 
―I personally can see the substance being very 
addicting‖ 
―There is actually an addictive property to Kratom‖  
―Six hours later I would start getting withdrawal 
effects‖ 
―I started getting withdrawal effects which was really a 
runny nose‖ 
―I had no energy, I felt sick‖ 
―I started getting shakes my body‖ and ―joint pain‖ 
―People become addicted‖ 




―Not a single person has died directly as a result of 
Kratom‖ 
―In three deaths Kratom was …in combination‖ 
―No one … died directly as a result of Kratom‖  
―To combine it with MAO inhibitors can be lethal‖ 
―Overdosing can cause seizures, coma, and death‖ 
4 
 
4. Discussion and conclusion 
Building on previous online surveys (Coe et al., 2019; Grundmann, 2017) and analysis 
of Kratom‘s experiences on fora (Swogger et al., 2015), our study is the first one to have 
considered the first-person video accounts shared on YouTube
TM
 to better understand uses, 
motivations, perceptions and potential risks related to its unsupervised applicability. Our 
findings show that Kratom is widely used for its medicinal value (see also section 3.1 and 
Table 2) as a natural remedy for self-treating a wide range of adverse health conditions, rather 
than for its psychoactive properties. The large majority of the most popular videos (58%) 
conveyed a positive message about its consumption and claimed that the substance can 
alleviate suffering from chronic pain, opioid, amphetamine-type-stimulant (ATS) and alcohol 
related problems, as well as improve mental and physical functioning. A state of opioid-like 
relaxation as well as other benefits that were more linked to the plant‘s psychostimulant (e.g., 
euphoria, increased sexual energy) and ―entactogenic‖ properties, such as enhanced 
communication, were often reported. Such claims are supported by literature where Kratom 
use is associated with mood elevation, anxiolysis, enhanced socialisation and nootropic 
effects (Bath et al., 2020; Swogger and Walsh, 2018), including in traditional settings, like 
Malaysia and Thailand, where the plant is commonly consumed for earning extra income and 
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enhancing productivity (Saingam et al., 2013). We also found the use of Kratom to ‗taper off‘ 
opioids, manage withdrawal symptoms, or as a substitute subsistence dose to minimise the 
risk of relapse in those who were dependent on illicit substances, since Kratom is not 
addictive like opioids and manage to help them overcome their opioid, or Substance Use 
Disorder (SUD). Such anecdotal reports would provide some support to Kratom‘s potential as 
an opioid substitute. Evidence of this has been previously collected in a few large survey-
based studies, which found that Kratom can help illicit and prescription opioid users refrain 
from, reduce and stop opioid use (Coe et al., 2019; Garcia-Romeu et al., 2020; Grundmann, 
2017) as well as a study where mitragynine, the primary alkaloid, showed to have limited 
abuse potential and the advantage to reduce morphine intake in rats (Hemby et al., 2019). 
Taken together, these findings would show that Kratom is widely used and known as a 
medicinal aid rather than a recreational NPS. However, this was not without risks, with 25% 
of the videos having a negative message, and the content reported in 50% of the examined 
videos referred to the risk of adverse/side effects (Table 3). These were mainly associated 
with chronic ingestions and the intake of higher doses of Kratom, leading to weakness, 
sweating, insomnia, runny nose, dizziness, loss of motivation, and constipation, dysphoria, 
and decrease of sexual desire. Cases of addiction, dependence, and withdrawal syndrome 
(e.g., tremors, anxiety, hostility, depression) were also reported. Some of these symptoms 
have already retrospectively been described in the scientific literature (Saref et al., 2019; 
Singh et al. , 2014), where it has also been suggested that the limited and misleading 
information on suggested doses in available sold Kratom products might have made the 
insurgence of unwanted effects even more likely (Williams and Nikitin, 2020). In addition, 
products bought from the internet or convenience stores might provide different effects than 
brewed Kratom juice, as they could be adulterated with other unknown substances which can 
lead users to experience deleterious health effects (Cinosi et al., 2015; Corkery et al., 2019; 
Nacca et al., 2020). However, some studies showed that long-term Kratom use do not seem to 
cause toxic effects on the haematology and biochemical parameters of Kratom users (Singh et 
al., 2018). Its discontinuation does not seem to cause withdrawal for about twenty hours 
(Vicknasingam et al., 2020) and Grundmann (2017) found those who use Kratom regularly 
did not experience any negative effects if they hold back their dose for more than 48 hours. In 
fact, a substantial percentage have also not sought medical or mental treatment from 
healthcare providers despite using Kratom for prolong periods. Moreover, results from a few 
large-scale studies reported Kratom‘s adverse reactions were usually mild and self-
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manageable and did not carry any significant risks (Coe et al., 2019; Garcia-Romeu et al., 
2020). This suggests that a monitored Kratom consumption is not associated with significant 
health problems and it is possible to think that its regular use in smaller amounts may be safe 
for its intended therapeutic properties. However, users may not have adequate information on 
Kratom‘s side-effects, as the literature on the topic is still poorly elucidated, with our study 
giving a little contribution on it. Finally, the content presented in the remaining 17% of the 
videos expressed a neutral more balanced view on the use of Kratom. 
Methodologically, the novel netnographic approach used for this study, that combined 
digital data (YouTube™ videos) and ―offline‖ automatic transcripts on Kratom use, provided 
a valuable source of information on Kratom‘s perceptions and use patterns. YouTube™ has 
been previously deployed with success to investigate the use of Salvia divinorum and 
psychedelic microdosing over which there is only minimal data from controlled studies 
available (Lange et al., 2010; Casselman and Heinrich 2011; Hupli et al., 2019). These studies 
made use of different data extraction techniques to produce generalizable samples, noting 
however that as the ecology of YouTube™ changes by the minute, it would be difficult to 
replicate these samples (Manning 2013). However, YouTube
TM
 has been used increasingly in 
the field of digital drug research for other emerging psychoactive substances (Johnstad, 2018; 
Kjellgren, Henningsson, and Soussan, 2013; Soussan and Kjellgren, 2014; Soussan et al., 
2018), showing that this netnographic exploration provides interesting insights into the effects 
and risks of substances use, and, in our case, helped to inform Kratom education needs, as 
well as provided insight on its safety and therapeutic benefits. It is important to consider that 
this method has some limits per se, since it does not allow an intensive data collection 
procedure. This aspect must be taken into account also to understand our study‘s limitations. 
Firstly, our data are limited to a self-selected and non-randomized small number of videos 
that could contribute to bias, and the authenticity of the claimed therapeutic benefits of 
Kratom use cannot be clinically confirmed since it is solely based on users‘ personal 
experiences and views, thus our findings from the YouTube™ videos cannot be generalised. 
As many videos included a mix of self-reported experiences with broader knowledge/views 
on Kratom, the percentages should be considered as indicative only of awareness of, not 
personal experience of any effect or side effect - the inclusion of a statement in the video is 
not meant to infer frequency of occurrence – i.e. people spoke about risk of serious side 
effect, without having experienced this themselves. Second, we only analysed English 
language videos, hence this reduces our ability to analyse other non-English videos and 
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provide a more comprehensive narration on the benefits of Kratom use. The collected 
evidence is not intended to compare with the self-reported data collected from surveys with a 
greater number of users (e.g. Grundmann, 2017). Instead, it provides an undirected, 
unsolicited view into the knowledge exchange provided on the YouTube™ platform. In 
absence of controlled clinical trials, it shares novel insights on the material available on the 
Internet that can be freely accessible by (potential) users, and forms the basis upon which 
people base their decision-making. It is hoped that our findings lend support for future 
investigations in the field and visibility to novel methods of data collection, capable of 
adapting to face-paced developments in how we share information. 
In conclusion, the results of our study helped to shed light on the less explored 
medicinal benefits of Kratom, rather than reinforcing its previous association with harmful 
effects typical of classical opioids. However, such findings require further contextualization 
outside the digital milieu of YouTube™, and further controlled clinical studies are needed to 
better understand the safety, therapeutic efficacy and long-term perils of Kratom use– if it is 
used to treat a wide range of health conditions. Finally, our work generates new critical 
questions on whether Kratom could be used as a natural remedy to mitigate the present opioid 
misuse epidemic.  
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